Hannah Joseph Hospitals BSE SME IPO: What the Numbers Reveal About a ₹159 Crore Valuation

A 150-hospital bed is now eyeing oncology for its next leg of growth, but will it pay off for new IPO investors?

Hannah Joseph Hospitals Ltd. began as a focused neuroscience facility in Madurai, Tamil Nadu, establishing itself as a specialized provider of neurosurgery and neurology services. Over the years, the hospital expanded its scope, adding cardiac sciences with a catheterization lab and cardiac operation theaters, enabling it to perform complex coronary angioplasties and open-heart surgeries.

The company operates from a two-acre campus in Madurai with 150 beds across a centrally air-conditioned facility. It holds NABH Accreditation for hospital standards and NABL 128 Certification for testing and calibration laboratories—credentials that signal compliance with national quality benchmarks in healthcare delivery.

In 2020, recognising space constraints and growing demand, the hospital relocated to its current expanded facility. This move marked a strategic shift from a specialized neuroscience center to a multi-specialty healthcare provider, though neurology, cardiology, psychiatry, and trauma care remain primary focus areas.

The hospital has secured empanelment under two significant government healthcare schemes in Tamil Nadu. Through MD India Healthcare Services as the third-party administrator, it participates in the Tamil Nadu New Health Insurance Scheme (TNNHIS), providing cashless medical treatment to state government employees, PSU workers, and related beneficiaries. It’s also empanelled under the Chief Minister’s Comprehensive Health Insurance Scheme (CMCHIS), offering coverage up to ₹5 lakh per family annually for economically vulnerable populations identified through the Socio-Economic Caste Census database.

As of November 30, 2025, the hospital employed 364 people—a substantially larger workforce than typical SME manufacturers, though lean for a 150-bed multi-specialty facility operating round-the-clock.

Financial Trajectory

Revenue growth has been steady. Total income climbed from ₹54.90 crore in FY23 to ₹63.63 crore in FY24, then to ₹77.90 crore in FY25—a cumulative increase of 42% over two years. The first half of FY26 generated ₹42.75 crore, suggesting annualized revenue could reach approximately ₹85-86 crore if the pace holds.

Profitability showed more dramatic improvement. Net profit rose from ₹1.01 crore in FY23 to ₹4.07 crore in FY24, then jumped to ₹7.21 crore in FY25. The first six months of FY26 delivered ₹5.12 crore in profit, pointing toward potential full-year earnings of ₹10-11 crore if trends continue.

The margin expansion tells an important story. PAT margins improved from a thin 1.85% in FY23 to 12.03% in H1-FY26—a remarkable trajectory for a hospital business. Return on capital employed peaked at 17.03% in FY25 before moderating to 10.41% in the recent six-month period. Average return on net worth over three years stood at 10.95%—respectable but unremarkable for a service business with lower capital intensity than manufacturing.

The company has never paid dividends since incorporation, retaining all earnings for expansion and operations.

The Oncology Bet

Hannah Joseph’s IPO centers on a single major capital deployment: establishing a Radiation Oncology Centre. Of the ₹42 crore being raised, ₹34.98 crore—a full 83% of gross proceeds—will fund this new facility. The balance goes toward general corporate purposes.

This represents a significant strategic pivot. The hospital built its reputation on neurosciences and has more recently developed cardiac capabilities. Now it’s entering radiation oncology, a capital-intensive specialty requiring expensive linear accelerators, specialized infrastructure, radiation physics expertise, and regulatory approvals that can take considerable time.

Cancer care is undeniably a growth area in Indian healthcare, with rising incidence rates and expanding insurance coverage creating demand. Madurai and surrounding areas of southern Tamil Nadu may well have unmet needs for radiation therapy services. But oncology is also highly competitive, with established players and other hospitals expanding into the space.

At the upper price band of ₹70, Hannah Joseph seeks a post-IPO market capitalization of ₹158.89 crore with paid-up equity expanding from ₹16.70 crore to ₹22.70 crore.

The asking price yields a P/E ratio of 22.01 based on FY25 earnings of ₹7.21 crore. Using annualized FY26 numbers brings the multiple down to 15.52.

Price-to-book value stands at 2.20 times NAV of ₹31.87 as of September 30, 2025. Curiously, the offer document omits post-IPO NAV data, making it difficult to assess dilution impact on book value multiples.

The offer document lists Asarafi Hospital (P/E of 22.4) and Maitreya Medicare (P/E of 894) as listed peers.

Promoters acquired their shares at an average cost between ₹0 and ₹13.06 per share across various issuances. Pre-IPO placements between March 2020 and February 2024 priced shares between ₹130 and ₹205, with bonus issues in the ratio of 5:1 and 1:2 in 2021 and 2022 respectively.The IPO price of ₹70 falls below those earlier placements on a pre-bonus adjusted basis, though the multiple bonus issues make the effective discount unclear.

Infrastructure and Scale Questions

A 150-bed facility with 364 employees generating ₹78 crore in annual revenue translates to roughly ₹52 lakh in revenue per bed annually, or about ₹1.42 lakh per day across all beds. These metrics sit in the middle range for multi-specialty hospitals—not exceptional, but reasonable.

The employee-to-bed ratio of 2.4:1 is lean for a multi-specialty hospital claiming capabilities in neurosciences, cardiac care, psychiatry, and trauma. For comparison, well-run corporate hospital chains often operate at 3-4 employees per bed when accounting for 24/7 staffing requirements, specialized departments, and support functions.

Adding radiation oncology to this mix increases complexity considerably. Oncology departments require radiation safety officers, medical physicists, dosimetrists, specialized nursing staff, and support personnel beyond typical hospital staffing patterns. Whether the current organizational structure can absorb this expansion without proportionally larger increases in operating costs remains to be seen.

Capital Square Advisors is handling its first SME mandate in the current fiscal year. The same group entity, CapitalSquare Financial Services, serves as market maker.

Risk Factors Worth Examining

The concentration of ₹35 crore into radiation oncology creates single-point execution risk. Equipment procurement, regulatory approvals, staffing specialized roles, building patient referral networks, and achieving utilization rates that justify the investment all need to proceed smoothly. In healthcare infrastructure, delays and cost overruns are more common than ahead-of-schedule, under-budget completions.

Madurai, while a significant urban center, isn’t Chennai or Bangalore. The catchment population and ability to attract patients from surrounding areas for specialized cancer treatment depends on factors beyond the hospital’s control: competing facilities, patient travel patterns, insurance coverage, and referral physician networks.

The expansion from focused neuroscience to multi-specialty and now oncology represents ongoing strategic shifts. Each specialty added dilutes organizational focus and stretches management bandwidth. Not all hospitals successfully navigate such transitions, particularly when led by medical professionals whose expertise lies in clinical care rather than business operations.

The Proposition

Hannah Joseph Hospitals’ margin expansion from sub-2% to 12% over three years represents meaningful operational improvement, whether from revenue mix, efficiency gains, or both. The NABH and NABL certifications indicate adherence to quality standards, and the government scheme empanelments provide institutional validation.

The question facing potential investors: is this a ₹159 crore business based on current operations and future prospects?

At 22 times FY25 earnings, investors are paying for continued growth and successful oncology expansion. The ₹35 crore oncology investment needs to generate sufficient returns to justify both its capital cost and the valuation premium embedded in the IPO price.

The subscription window opens January 22 and closes January 27, 2026. Minimum application is 4,000 shares, requiring ₹2.80 lakh at the upper price band.

Issue Details